CURE hosted a Legislative Briefing at the State Capitol in Hartford February 23, attended by CURE members, Connecticut legislators, and Governor Dannel Malloy. The subject was “Biotech Drug Discovery, Innovation, Process and Talent.”

After Governor Malloy’s opening remarks and an introduction by CURE board member Anthony Sabatelli, Dr. Erin Duffy, Chief Scientific Officer of Melinta Therapeutics, described the long and risky road of drug development from initial concept to marketed product.

 

Then Mr. Christian Steele, Senior Director, Talent Acquisition, at Alexion, discussed the challenges of attracting and retaining the top talent needed for drug discovery.

Next a panel of experts discussed the business of biotech, including business development activities, financing rounds, research and development partnerships, licensing deals, and exit strategies. The panel included Dr. Susan Froshauer, CEO of CURE, Mr. Bill Claffey, a Partner at the accounting firm of Fiondella, Milone & LaSaracina, in Glastonbury, and Mr. Stan Choy, Co-Chair and Treasurer of CURE.

 

CURE appreciates the recognition by the Governor of how critical the biotech industry is to the long-term health of the state and acknowledges the outstanding support the State has shown for the industry. Continuing the dialog, CURE will be hosting a major BioHaven seminar April 25 on the important topic of biopharma drug pricing.